Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones

Journal of Medicinal Chemistry

Volumn 42, Issue 11, 1999, Pages 1927-1940

  Reddy, K Anji ^e   Lohray, B B ^a,b   Bhushan, V ^a,b   Bajji, A C ^b   Reddy, K Vivekananda ^b   Reddy, P Rajamohan ^b   Krishna, T Hari ^b   Rao, I Nageswara ^b   Jajoo, H Kumar ^c   Rao, N V S Mamidi ^c   Chakrabarti, Ranjan ^d   Dileepkumar, T ^d   Rajagopalan, R ^d  

^a ZYDUS RESEARCH CENTRE   (India)

^b Medicinal and Organic Chemistry   (India)

^c Drug Metabolism and Pharmacokinetics   (India)

^d Pharmacology   (India)

^e DR REDDY S RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDEHYDE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BENZOFURAN DERIVATIVE; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; DRUG TRANSFORMATION; ELECTRON TRANSPORT; FEMALE; HYDROGENATION; MALE; MOUSE; NONHUMAN; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; FEMALE; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; PYRROLIDINES; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 0033519652     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980549x     Document Type: Article

References (50)

1. Sohda, T.; Mizuno, K.; Tawada, H.; Sugiyama, Y.; Fujita, T.; Kawanatsu, Y. Chem. Pharm. Bull. 1982, 30, 3563-3573 and 3580-3600.
2. (a) Momose, Y.; Meguro, K.; Ikeda, H.; Hatanaka, C.; Oi, S.; Sohda, T. Studies on antidiabetic agents X synthesis and biological activities of pioglitazone and related compounds. Chem. Pharm. Bull. 1991, 39, 1440-1445.
3. (b) Sohda, T.; Mizuno, K.; Momose, Y.; Ikeda, H.; Fujita, T.; Meguro, K. Studies on Antidiabetic Agents. 11. Novel Thiazolidinedione Derivatives as Potent Hypoglycemic and Hypolipidemic Agents. J. Med. Chem. 1992, 35, 2617-2626.
4. (c) Yoshioka, T.; Fujita, T.; Kanai, T.; Aizawa, Y.; Kurumada, T.; Hasegawa, K.; Horikoshi, H. Studies on Hindered Phenols and analogous. 1. Hypolipidemic Agents with ability to Inhibit Lipid peroxidation. J. Med. Chem. 1989, 32, 421-428.
5. (d) Clark, D. A.; Goldstein, S. W.; Volkmann, R. A.; Eggler, J. F.; Holland, G. F.; Hulin, B.; Stevenson, R. W.; Kreutter, D. K.; Gibbs, E. M.; Krupp, M. N.; Merrigan, P.; Kelbaugh, P. L.; Andrews, E. G.; Tickner, D. L.; Suleske, R. T.; Lamphere, C. H.; Rajeckas, F. J.; Kappeler, W. H.; McDermott, R. E.; Hutson, N. J.; Johnson, M. R. Substituted Dihydrobenzopyran and Dihydrobenzofuran Thiazolidine-2,4-diones and Hypoglycemic Agents. J. Med. Chem. 1991, 34, 319-325.
6. (e) Lohray, B. B.; Bhushan, V.; Rao, P. B.; Madhavan, G. R.; Murali, N.; Rao, K. N.; Reddy, K. A.; Rajesh, B. M.; Reddy, P. G.; Chakrabarti, R.; Rajagopalan, R. Bioorg. Med. Chem. Lett. 1997, 7, 785.
7. (f) Arakawa, K.; Inamasu, M.; Matsumoto, M.; Okumura, K.; Yasuda, K.; Akatsuka, H.; Kawanami, S.; Watanabe, A.; Homma, K.; Saiga, Y.; Ozeki, M.; Iijma, I. Novel Benzoxazole 2,4-thiazolidinediones as Potent Hypoglycemic Agents Synthesis and Structure-Activity Relationships. Chem. Pharm. Bull. 1997, 45, 1984-1993.
8. (a) Steiner, K. E.; Lien, E. L. Hypoglycemic Agents which do not Release Insulin. In Progress in Medicinal Chemistry; Ellis, G. P., West, C. B., Eds.; Elsevier. Oxford, 1987; Vol. 24, pp 209-248.
9. (b) Larson, E. R.; Clark, D. A.; Stevenson, R. W. New Approaches to Diabetes. Annu. Rep. Med. Chem. 1989, 25, 205-213.
10. (c) Colea, J. R.; Tanis, S. P. Recent advances in the discovery and development of potential antidiabetic agents. Annu. Rep. Med. Chem. 1992, 27, 219-226.
11. (d) Dow, R. L.; Kreutter, D. K. Recent Advancements in the Discovery and Development of Agents for the Treatment of Diabetes. Annu. Rep. Med. Chem. 1995, 30, 159-168.
12. (e) Hulin, B.; McCarthy, P. A.; Gibbs, E. M. The Glitazone Family of Antidiabetic Agents. Curr. Pharm. Des. 1996, 2, 85-102.
13. (f) Hulin, B. New Hypoglycemic Agents. Prog. Med. Chem. 1994, 31, 1-58.
14. Fujita, T.; Sugiyama, Y.; Taketomi, S.; Sohda, T.; Kawamastsu, Y.; Iwatsuka, H.; Suzuoki, Z. Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexyl-methoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878,U,63287, Ciglitazone), a New Antidiabetic Agent. Diabetes 1983, 32, 804-810.
15. (a) Williams, D. G.; Deldar, A.; Jordan, W. H.; Gries, C.; Long, G. G.; Dimarchi, R. D. Subchronic Toxicity of the Thiazolidinedione, Tanabe 174, in Rat and Dog. Diabetes 1993, 42 (Suppl. 1), 59A (Abstr. 186).
16. (b) Deldar, A.; William, G.; Stevenes, C. Pathogenesis of Thiazolidinedione induced haemotoxocity in the dog. Diabetes 1993, 42 (Suppl. 1), 57A (Abstr. 179).
17. Troglitazone is being marketed in the United States as Rezulin and in Japan as Noscal.
18. Matsumoto, K.; Miyake, S.; Yano, M.; Ueki, Y.; Tominaga, Y. Increase of Lipoprotein (a) with Troglitazone. Lancet 1997, 350, 1748-1749. Please see also Scrips 1997, 2282, 21.
19. Matsumoto, K.; Miyake, S.; Yano, M.; Ueki, Y.; Tominaga, Y. Increase of Lipoprotein (a) with Troglitazone. Lancet 1997, 350, 1748-1749. Please see also Scrips 1997, 2282, 21.
20. (b) Scrips 1997, 2292, 20.
21. (a) Fujiwara, T.; Yoshioka, S.; Yoshioka, T.; Ushiyama, I.; Horikoshi, H. Characterization of New Oral Antidiabetic Agent CS-045. Diabetes 1988, 37, 1549-1558.
22. (b) Hulin, B.; Clark, D. A.; Goldstein, S. W.; McDermott, R. E.; Dambek, P. J.; Kappeler, W. H.; Lamphere, C. H.; Lewis, D. M.; Rizzi, J. P. Novel Thiazolidine-2,4-diones as Potent Euglycemic Agents. J. Med. Chem. 1992, 35, 1853-1864.
23. (c) Cantello, B. C. C.; Cawthorne, M. A.; Haigh, D.; Hindley, R. M.; Smith, S. A.; Thurlby, P. L. The Synthesis of BRL-49653 - A Novel and Potent Antihyperglycemic agent. Bioorg. Med. Chem. Lett. 1994, 4, 1181-1184.
24. (d) Cantello, B. C. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. [(ω-(Heterocyclylamino)alkoxy]-benzyl]-2,4-thiazolidinediones as potent Antihyper glycemic agents. J. Med. Chem. 1994, 37, 3977-3985.
25. For non-thiazolidinedione-like agents, see: (a) Kees, K. L.; Cheeseman, R. S.; Prozialeck, D. H.; Steiner, K. E. Perfluoro-N-[4-(1H-tetrazol-5-ylmethyl)phenyl]alkanamides. A New Class of Oral Antidiabetic Agents. J. Med. Chem. 1989, 32, 11-13.
26. (b) Kees, K. L.; Fitzgerald, J. J., Jr.; Steiner, K. E.; Mattes, J. F.; Mihan, B.; Tosi, T.; Mondoro, D.; McCaleb, M. L. New Potent Antihyperglycemic Agents in db/db mice: Synthesis and structure Activity Relationship Studies of 4-substituted benzyl (trifluoromethyl) pyrazoles and Pyrazolones. J. Med. Chem. 1996, 39, 3920-3928.
27. (c) Hulin, B.; Newton, L. S.; Lewis, D. M.; Genereux, P. E.; Gibbs, E. M.; Clark, D. A. Hypoglycemic Activity of a series of α-Alkylthio and α-Alkoxy Carboxylic Acids related to Ciglitazone. J. Med. Chem. 1996, 39, 3897-3907.
28. (d) Kees, K. L.; Caggiano, T. J.; Steiner, K. E.; Fitzgerald, J. J., Jr.; Kates, M. J.; Christos, T. E.; Kulishoff, J. M.; Moore, R. D.; McCaleb, M. L. Studies on New Acidic Azoles as Glucose Lowering Agents in Obese, Diabetic db/db mice. J. Med. Chem. 1995, 38, 617-628.
29. (e) Wrobel, Ji-Li Z.; Dietrich, A.; McCaleb, M.; Mihan, B.; Sredy, J.; Sullivan, D. Novel 5-(3-Aryl-2-propynyl)-5-(arylsulfonyl)-thiazolidine-2,4-diones as Antihyperglycemic Agents. J. Med. Chem. 1998, 41, 1084-1091.
30. (f) Shinkai, H.; Onogi, S.; Tanaka, M.; Shibata, T.; Iwao, M.; Wakitani, K.; Uchida, I. Isoxazolidine-3,5-dione and Noncyclic-1,3-dicarbonyl compounds as hypoglycemic Agents. J. Med. Chem. 1998, 41, 1927-1933.
31. For 2,4-oxazolidinediones, see: Dow, R. L.; Bechle, B. M.; Chou, T. T.; Clark, D. A.; Hulin, B.; Stevenson, R. W. Benzyloxazolidine-2,4-diones as Potent Hypoglycemic Agents. J. Med. Chem. 1991, 34, 1538-1544.
32. (a) Goldstein, S. W.; McDermott, R. E.; Gibbs, E. M.; Stevenson, R. W. Hydroxyurea Derivatives as Hypoglycemic Agents. J. Med. Chem. 1993, 36, 2238-2240.
33. (b) Kees, K. L.; Caggiano, T. J.; Steiner, K. E.; Fitzgerald, J. J., Jr.; Kates, M. J.; Christos, T. E.; Kulishoff, J. M., Jr.; Moore, R. D.; McCaleb, M. L. Studies on New Acidic Azoles as Glucose Lowering Agents in Obese, Diabetic db/db mice. J. Med. Chem. 1995, 38, 617-628.
34. (a) Lohray, B. B.; Bhushan, V.; Bheema Rao, P.; Madhavan, G. R.; Murali, N.; Rao, K. N.; Reddy, K. A.; Rajesh, B. M.; Reddy, P. G.; Chakrabarti, R.; Vikramadithyan, R. K.; Rajagopalan, R.; Rao, N. V. S. Mamidi; Jajoo, H. K.; Subramaniam, S. Novel Euglycemic and Hypolipidaemic Agents. Part 1. J. Med. Chem. 1998, 47, 1619-1630.
35. Reddy, K. A.; Lohray, B. B.; Bhushan, V.; Reddy, A. S.; Kishore, P. H.; Rao, V. V.; Saibaba, V.; Bajji, A. C.; Rajesh, B. M.; Reddy, K. V.; Chakrabarti, R.; Rajagopalan, R. Novel Euglycemic and Hypolipidemic Agents: Part 2: Antioxidant Moiety as Structural Motif. Bioorg. Med. Chem. Lett. 1998, 9, 999-1002.
36. Takebayashi, T.; Onodera, T.; Hasegawa, K.; Fujita, T.; Yoshioka, T. E. P. 454 501, 1991; Chem. Abstr. 1992, 116, 59361k.
37. Watt, S. D.; Profitt, J. A.; Corey, E. J. A Reagent for α,β-Reduction of conjugated Nitriles. J. Org. Chem. 1975, 40, 127-128.
38. (a) Hammer, C. F.; Heller, S. R.; Carig, J. H. Reactions of β-substituted Amines II-Nucleophilic displacement reaction 3-chloro-1-ethylpiperidine. Tetrahedron 1972, 28, 239-253.
39. (b) Chavdarian, C. G.; Sanders, E. B.; Bassfield, R. L. Synthesis of optically active Nicotinoids. J. Org. Chem. 1982, 47, 1069-1073.
40. Calculation: The percent reduction was calculated according to the formula TT, test day treated; OT, zero day treated; TC, test day control; OC, zero day control. Statistics: All results are expressed as mean ± SE. The AUC was calculated according to the trapezoidal rule. ANOVA was used for testing for significance between the control and treated groups. P value which is <0.05 is considered as significant.
41. Englitazone was obtained from Pfizer Inc. on personal request.
42. (a) Horikoshi, H.; Yoshio, T.; Kawasaki, T.; Nakamura, K.; Matsunuma, N.; Yamaguchi, K.; Sasahara, K. Troglitazone (CS-045), A New Antidiabetic Drug. Annu. Rep. Sankyo Res. Lab. 1994. 46, 1-57.
43. (b) Kobayashi, M. Thiazolidinediones in the treatment of Insulin Resistance and NIDDM: Current Status and Future Side. 56th ADA Meeting, San Francisco, CA, 1996.
44. 2 is a Ligand for the Adipocyte Determination Factor PPARγ. Cell 1995. 83, 803-812.
45. (b) Lehman, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An Antidiabetic Thiazolidinedione is a High Affinity Ligands for Peroxisome Proliferator-activated Receptor γ (PPARγ). J. Biol. Chem. 1995, 270, 12953-12956.
46. (c) Forman, B. M.; Chen, J.; Evans, R. M. Hypolipidemic drugs, Polyunsaturated fatty acids and eicosanoids are ligands for PPARα and δ. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4312-4317.
47. Aicher, T. D.; Balkan, B.; Bell, P. A.; Brand, L. J.; Cheon, S. H.; Deems, R. O.; Fell, J. B.; Fillers, W. S.; Fraser, J. D.; Gao, J.; Knorr, D. C.; Kahle, G. G.; Leone, C. L.; Nadelson, J.; Simpson, R.; Smith, H. C. Substituted Tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and Tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as Hypoglycemic Agents. J. Med. Chem. 1998, 41, 4556-4566.
48. Kawai, K.; Kawasaki-Tokui, Y.; Odaka, T.; Tsuruta, F.; Kazui, M.; Iwabuchi, H.; Nakamura, T.; Kinoshita, T.; Ikeda, T.; Yoshioka, T.; Komai, T.; Nakamura, K.-i. Disposition and Metabolism of New Oral Antidiabetic drug troghitazone in Rats, Mice and Dogs. Arzneim. Forsch. 1997, 47, 356-368.
49. B. B. Lohray et. al. unpublished results.
50. Daumas, M.; Vo-Quant, Y.; Vo-Quang, L.; Le Goffic, F. A New and Efficient Heterogeneous system for the oxidative cleavage of 1,2-Diols and the Oxidation of Hydroquinones. Synthesis 1989, 64-65.